GalenOps prod · 0.1.0

Agent

Drug supply forecast

Partner supply_agent

Kits required over the horizon from observed dosing, accrual and discontinuation (partner IRT).

Escalates: Nothing — purely operational. The kit forecast is handed to the IRT/RTSM partner, where humans act on it — to the IRT/RTSM partner (integration boundary).

Agents

Runs

3

Escalations

0

Failures

0

Avg duration

3.8 s

Literature & benchmarks

  • Dosing-derived kit forecast — enrolled × retention × dosing schedule over the horizon, plus a 15% buffer
  • IRT/RTSM partner boundary — GalenOps forecasts; the vendor dispenses and resupplies

Run history (3 across all studies)

Newest first, 50 per page. Expand a row for the recorded reasoning and evidence.

Expand When Study Outcome Model Duration Reasoning
2026-09-29 23:42 UTC A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma completed claude-sonnet-5 3.7 s This study is completed, so the report is retrospective rather than a forward forecast. Across the trial, 573 IP kits (Aldoxorubicin (INNO-206) and Doxorubicin) were dispensed to 123 patients, averaging 4.7 kits per patient. Dosing was observed at 1.33 administrations per 28 days, with median doses of 350.0 mg/m2 (Aldoxorubicin) and 75.0 mg/m2 (Doxorubicin). The observed monthly stop rate was 38.7%, giving a retention rate of 0.613 (123 stops over 317.7 patient-months). Of the 573 kits dispensed, 45 kits (7.9%) went to patients who later withdrew, serving as a waste proxy. No forward-looking forecast was generated since the study status is "completed" and there are 0 patients on treatment. No thresholds were breached and no review task was opened in this summary.
2026-09-29 21:13 UTC A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer completed claude-sonnet-5 3.5 s The forecast projects 1,675 blinded kits (PLACEBO/TORIVUMAB) needed over the 6-month horizon, including a 15.0% kit buffer, versus 1,769 kits previously — a -5.3% change in demand, consistent with the escalation record. This reflects 122 patients on treatment at 1.33 administrations/28 days, accrual of 20.33 patients/month (61 consents in the trailing 90 days), and an observed monthly stop rate of 4.4% (retention 0.956). All 15 sites are activated and none are flagged at_risk; the tightest site is SITE012 (BRA) with 6.3 weeks of cover, above any at-risk threshold implied here. Escalation shows task_opened as false and tight_sites empty, so no review task was generated. No human decision is required at this time based on the evidence provided.
2026-09-19 08:59 UTC A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer completed claude-sonnet-5 4.2 s The forecast projects 1769 blinded kits needed over 6 months, including the 15.0% kit buffer, covering 127 patients on treatment at 1.33 administrations/28 days, with 379.77 new-patient-months from 133 projected new patients (accrual 22.17/month, capped at the 450-patient target) plus 681.25 current patient-months. Monthly stop rate is 4.5% (retention 0.955), based on observed data from 69 stops among 307 dosed patients. The tightest site is SITE014 (NLD) at 6.0 weeks of cover, with a depot assumption of 2 months' current burn; no site is flagged at_risk, and escalation shows task_opened: false with no tight_sites listed. This is the first recorded forecast for this study (previous_enrollment and previous_kits are null). No threshold breach or escalation is indicated, so no human decision is required at this time.